Thymosin Alpha-1

The Thymosin Alpha-1 evidence base cited here is 8 sources — 3 clinical, 1 preclinical, 2 review, 1 regulatory. Its strongest evidence is human — 3 clinical studies, most recently 2025 ("Effect of Thymosin Alpha-1 on 28-Day Mortality in Adults with Sepsis: Th…"). Regulatory status: Approved in 30+ countries.

• Thymosin Alpha 1 (Tα1) is a natural 28-amino-acid thymus peptide that modulates the immune system — it's the amino-terminal segment of prothymosin alpha, first isolated in 1977.
• It's unusual among immune compounds for being homeostatic: it can boost an underactive immune response AND dampen an overactive inflammatory one, rather than just stimulating.
• It has the deepest real-world clinical track record of the immune peptides — the synthetic version (Zadaxin / thymalfasin) is approved in 35+ countries for hepatitis B/C and as a cancer adjuvant, though NOT by the US FDA.

Thymosin Alpha 1 is a naturally occurring 28-amino-acid peptide from the thymus gland that acts as a master regulator of immune balance. It's studied and used for viral infections, immune reconstitution, and as a cancer-therapy adjunct, and is popular with longevity and immune-optimization crowds.

What makes it stand out from most research peptides: it has genuine pharmaceutical approval in much of the world (as Zadaxin) and a decades-deep clinical literature — so the framing here leans on real trial data. The honest counterweight is that its two biggest historical use cases have weakened: hepatitis (eclipsed by modern antivirals) and sepsis (a large 2025 Phase 3 trial found no benefit). It's still not FDA-approved. Everything below is research context, not medical advice.

First isolated from thymic tissue in 1977 by Allan Goldstein's group at George Washington University, Tα1 is the amino-terminal fragment of prothymosin alpha and a key regulator of immune homeostasis. The synthetic drug form is thymalfasin, marketed as Zadaxin.

Its defining trait is dual-direction regulation. Where conventional immunostimulants only push the immune system up, Tα1 enhances immune surveillance when responses are weak yet promotes tolerance mechanisms that restrain overactive inflammation — a homeostatic rather than purely stimulatory profile.

Dosing is better established than most research peptides because of its pharmaceutical history, but it's still not FDA-approved. Figures below reflect clinical-trial and practitioner use, for research context only.

• Immune support/maintenance: 1.6 mg subcutaneously twice weekly (the most common starting dose).
• Acute viral infection / cancer adjunct: 1.6 mg daily or 3.2 mg twice weekly initially; up to 6.4 mg twice weekly in severe cases under medical supervision.
• Hepatitis B trials used 1.6 mg twice weekly for 6–12 months.
• Cycling: it doesn't appear to cause receptor downregulation/tachyphylaxis, so continuous use is common for chronic conditions; some run 8–12 weeks on / 4 weeks off prophylactically.

No meaningful tachyphylaxis is a genuine point of difference from anabolic compounds — sustained protocols don't seem to lose potency.

Subcutaneous injection is standard — oral bioavailability is poor (GI degradation), so it must be injected.

• Fine insulin syringe (29–31 g) into subcutaneous fat at 45–90°; sites: abdomen (≥2 in from the navel), anterior thigh, posterior upper arm. Rotate sites.
• Timing is flexible — any time of day, with or without food; some prefer morning to align with circadian immune rhythms, but no evidence mandates a specific time.
• Keep a consistent schedule (e.g. Mon/Thu) for twice-weekly protocols to maintain steady exposure.

• Weeks 1–2: cellular-level immune priming; usually no subjective change, though some note more energy or fewer minor infections.
• Weeks 2–4: detectable increases in T-cell subsets and NK-cell activity; enhanced vaccine response if immunized in this window.
• Weeks 4–8: clearer clinical benefit — fewer infections, faster recovery, improved chronic-viral markers in some.
• Weeks 8–24: sustained immune reconstitution in the immunocompromised; hepatitis B trials saw optimal virological response at 6–12 months.

These timelines are grounded in clinical trial data more than anecdote — a stronger footing than most peptides in this space.

Tα1 is one of the most-studied immune peptides, but the evidence is uneven across indications — strong in some, since-superseded or negative in others.

• Hepatitis B: meta-analyses showed ~36–40% sustained virological response as monotherapy, >50% combined with interferon-α — but this approach is now largely obsolete given >95%-effective direct-acting antivirals.
• Hepatitis C: improved sustained response when added to pegylated interferon + ribavirin, especially in hard-to-treat genotypes.
• Cancer adjunct: trials in hepatocellular carcinoma, melanoma, and NSCLC reported better outcomes alongside chemotherapy (one advanced-NSCLC study extended median survival ~8→12 months).
• Vaccine adjuvant: enhanced antibody response to influenza vaccination in elderly/immunocompromised groups.

Combined with other immunomodulators or recovery peptides. Combinations beyond the interferon protocols aren't formally trialed. Research context, not protocol advice.

• Tα1 + TB-500 (Thymosin Beta-4) — immune support (Tα1) plus tissue repair/anti-inflammatory (TB-4); popular for recovering from illness/injury.
• Tα1 + BPC-157 — adds gut-healing and systemic anti-inflammatory action via the gut-immune axis.
• Tα1 + interferon-α — clinically established for hepatitis with documented antiviral synergy.
• Tα1 + low-dose naltrexone (LDN) — used by some for immune modulation; formal trial data is limited.

• Reconstitute lyophilized powder with bacteriostatic water added slowly down the vial wall; let dissolve over 1–2 min, don't shake.
• Typical ratio: 5 mL BAC water per 5 mg vial = 1 mg/mL (a 1.6 mg dose = 1.6 mL).
• Unreconstituted: stable at room temp for a while, better refrigerated (2–8°C) long-term. Reconstituted: refrigerate, use within ~28–30 days; never freeze; protect from light.

Tα1 has an exceptional safety record across clinical trials and decades of pharmaceutical use — adverse effects are mild and infrequent, consistent with an endogenous peptide.

No serious adverse events have been attributed to Tα1 in controlled trials — among the cleanest safety profiles of any peptide here.

• The synthetic drug (thymalfasin/Zadaxin) holds US FDA orphan-drug designation for hepatitis B and hepatocellular carcinoma but no full FDA approval for any indication.
• Approved and marketed in 35+ countries (Italy, the Philippines, and many Asian/South American nations).
• US: not a controlled substance; available from compounding pharmacies with a prescription, or as a 'research chemical.'
• The FDA's 2023 compounded-peptide guidance did NOT place Tα1 on the 'difficult to compound' list, preserving compounding-pharmacy access.

Thymosin Alpha 1 is NOT currently on the WADA Prohibited List (as of 2026) — a notable contrast with Thymosin Beta-4/TB-500, which is banned. Its immunomodulatory rather than tissue-growth mechanism has kept it off the registry. That said, prohibited lists are revised annually, so tested athletes should verify current status before use rather than assume it stays permitted.

On the Huberman Lab podcast, Dr. Abud Bakri framed thymosin alpha-1 as 'jet fuel for T-cells' and part of a broader case that the thymus is the field's most underrated target. The thymus trains T-cells, involutes after puberty (driven by sex and stress hormones), and its decline tracks with rising cancer and autoimmunity; he cited Greg Fahy's TRIIM trial (GH + metformin + DHEA), which actually regrew thymic tissue and improved immune markers.

His most practical, low-cost takeaway: a standard CBC yields a lymphocyte-to-monocyte ratio that correlates with outcomes across many diseases yet is almost never examined clinically. He reported using thymosin alpha-1 himself when traveling and on hospital rotations (he cited roughly 2.5 mg twice weekly) and not getting sick — an anecdote, not a protocol recommendation.

Expert opinion and one physician's personal use; thymosin alpha-1 is approved abroad (Zadaxin) but is not FDA-approved in the US.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.